RLYB PEER ANALYSIS

Rallybio Corp — metric-by-metric comparison with peers and the industry median

RLYBRallybio Corp

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
RLYBIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
RLYB+512.2%RTALB+24.1%MSB+27.6%TLX-29.5%
Year-to-Date (YTD)
RLYB+188.1%RTALB+5.0%MSB-24.3%TLX+50.7%

Key Metric Comparison

P/E

Lower is better
RLYBRTALB4.89MSBTLXMedian 17.91

ROE

Higher is better
RLYB-15.0%RTALB15.1%MSB-11.3%TLX-1.8%Median -47.5%

Net Margin

Higher is better
RLYB-911.1%RTALB136.3%MSB-115.3%TLX-0.9%Median -125.7%

Revenue Growth

Higher is better
RLYB1.2%RTALB24.0%MSB410.4%TLX56.3%Median 5.1%

All Metrics

Valuation
MetricRLYBRTALBMSBTLXInd. Median
P/E4.8917.91
P/B1.790.616.373.51
EV/EBITDA74.61120.1414.82
P/S104.856.6731.613.2410.89
Financial Health
MetricRLYBRTALBMSBTLXInd. Median
Current Ratio12.921.211.435.90
Debt/Equity0.3%1.2%112.3%10.9%
NetDebt/EBITDA1.660.9013.131.15
Profitability
MetricRLYBRTALBMSBTLXInd. Median
Net Margin-911.1%136.3%-115.3%-0.9%-125.7%
ROE-15.0%15.1%-11.3%-1.8%-47.5%
ROA-13.9%13.1%-8.6%-0.7%-35.8%
EBITDA Margin-3,270.4%9.0%-76.6%3.0%-105.8%
Growth + Dividend
MetricRLYBRTALBMSBTLXInd. Median
Rev. Growth1.2%24.0%410.4%56.3%5.1%
NI Growth134.0%12.1%
Div. Yield0.0%0.0%0.2%
Payout0.0%0.0%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on RLYB

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.